Dr Benjamin Buckley. Photo by James Grabowski.

Dr Benjamin Buckley is heading to the United States

Cancer researcher Dr Benjamin Buckley has won a 2-minute pitch competition at the Bridge Training program in Sydney.

The prize is a travel grant to the United States. Later this month he will travel to the US to visit the headquarters of AMGEN, AbbVie and MSD (Bridge Program Consortium Partners) .

The program consisted of presentations and intensive pitching sessions delivered by stakeholders from across the Australian biopharma ecosystem. This included significant contributions by senior delegates from global pharmaceutical companies (e.g. AbbVie, Amgen, Merck, Pfizer).

 “This was an invaluable experience and allowed me to network with key people who otherwise would be inaccessible.”

Dr Buckley’s winning pitch detailed some of the amiloride derivatives he has helped develop at IHMRI.

His entry was chosen along with three others, and the winners and the pitches were screened at the conference dinner. 

“This will be an excellent opportunity for me to network with people able to support our aspirations to commercialise our research and to highlight the work being done at IHMRI and University of Wollongong (UOW). I’m thoroughly looking forward to it!”

“One of the other winners, Lilly Bojarski from BioLink Australia, presented a pitch concerning Deflexifol, another UOW technology contributed to by IHMRI researchers, Professor Marie Ranson, Professor Philip Clingan OAM and Emeritus Professor John Bremner.”

“Thank you once again for your support. I’m inspired by our direction as an institute and I feel privileged to represent IHMRI in this way.”

Read more about BridgeTech Program.

Media contact

Louise Negline, Communications Coordinator

t: 4221 4702 m: 0417 044 867

e: louisenegline@ihmri.org.au

Pictured: Research Fellow, Dr Benjamin Buckley

Photo: James Grabowski


You may also like

Grant success for motor neurone disease research
Could having a snack before bed aid in GDM management?
Should a bedtime snack be recommended for women with gestational diabetes?
COVID-19 impacts could slow research by ten years